With so many shares to choose from on the ASX, it can be hard to decide which ones to buy.

The good news is that brokers across the country are doing a lot of the hard work for you.

Three top shares that leading brokers have named as buys this week are listed below. Here’s why they are bullish on them:

Adairs Ltd (ASX: ADH)

According to a note out of Goldman Sachs, its analysts have retained their buy rating and lifted the price target on this homewares retailer’s shares to $2.80. Goldman likes Adairs due to its strong online business, improving supply chain, and attractive valuation. In respect to the latter, the broker estimates that Adairs’ shares are changing hands at just 10x FY 2022 earnings. It believes this offers a compelling risk/reward. I think Goldman makes some great points and Adairs could be worth considering.

Nick Scali Limited (ASX: NCK)

A note out of Citi reveals that its analysts have retained their buy rating and lifted their price target on this furniture retailer’s shares to $8.20. It believes that its strong order book is a sign that FY 2021 will be a solid year. In addition to this, the broker feels that Nick Scali’s target demographic are less likely to lose their jobs once the JobKeeper program ends. I think Citi could be on the money with this one and Nick Scali could be worth a closer look.

Westpac Banking Corp (ASX: WBC)

Analysts at Morgans have retained their add rating and lifted the price target on this banking giant’s shares to $22.50. According to the note, the broker believes that the bad debt damage being factored into its share price is overdone. Morgans doesn’t believe the bad debt experience during the pandemic will be as severe as that experienced during the GFC. I agree with Morgans on Westpac and would be a buyer of its shares.

More reading

• Here are 3 ASX 200 shares with dividend yields over 8%
• The NAB share price has fallen 24%. Should you buy?
• ASX 200 Weekly Wrap: ASX back in the green
• Beat low interest rates with Telstra and these ASX dividend shares
• Consider these blue chip ASX shares for strong dividend yields

Motley Fool contributor James Mickleboro owns shares of Westpac Banking. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Leading brokers name 3 ASX shares to buy today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/31aQ5ia

At the weekend I looked into how investments of $20,000 in a number of popular ASX shares fared over the last 10 years.

Given the success of these investments, I thought I would look at a few shares which I feel investors ought to consider investing $20,000 into today for the next decade.

Here why I think these three ASX shares could provide strong returns for investors:

Bravura Solutions Ltd (ASX: BVS)

I think that Bravura Solutions could be worth considering for a $20,000 investment. Bravura provides software and services to the wealth management and funds administration industries. Demand for its offering has been increasing other the last few years and has underpinned strong earnings growth. The good news is that it has added to its offering over the last 12 months through acquisitions. This has not only strengthened its portfolio, but opened up the company to new and lucrative markets.

iShares Global Healthcare ETF (ASX: IXJ)

Another option to consider investing $20,000 into is the iShares Global Healthcare ETF. I think this exchange traded fund could provide strong returns for investors over the 2020s thanks to the growing demand for healthcare services. This is expected to be driven by improvements in technologies, ageing populations, and increased chronic disease. The iShares Global Healthcare ETF gives investors exposure to the world’s biggest and best healthcare companies. This includes the likes of CSL Ltd (ASX: CSL), Johnson & Johnson, Novartis, and Pfizer.

REA Group Limited (ASX: REA)

A final option I would put $20,000 into is REA Group. It is a leading property listings company with real estate websites in Europe, Asia, the United States, and of course Australia. Although REA Group has experienced a sizeable reduction in listings during the pandemic, it has offset its weaker revenues through cost cutting. I believe this demonstrates the resilience of its business model and positions it well to accelerate its earnings growth when the headwinds it is facing ease.

More reading

• ASX 200 Weekly Wrap: ASX back in the green
• These fantastic healthcare ASX shares could make you wealthy
• How to turn $20,000 into $250,000 in 10 years with ASX shares
• How to become a millionaire in 25 years with $20 a day
• Why I’m desperate to add CSL and 2 other ASX shares to my portfolio in 2020

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Bravura Solutions Ltd and CSL Ltd. The Motley Fool Australia has recommended Bravura Solutions Ltd and REA Group Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Where to invest $20,000 into ASX shares immediately appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2zPy1iq

The Blackmores Limited (ASX: BKL) share price has struggled to gain momentum in recent years. After sliding heavily from mid 2018 to early 2019, Blackmores has since failed to regain these share price losses. The company’s Chinese business, in particular, has underperformed, no doubt contributing to its lack lustre share price performance.

In a recent capital raising, Blackmores successfully raised $92 million at a fixed price of $72.50 per share. Around $50 million of these funds will be used to strengthen the company’s balance sheet. The remainder will be used to support Blackmores’ activities in the Asian market as part of its turnaround strategy.

So, is the Blackmores share price in the buy zone right now?

Rising demand for immunity products offset by other challenges

In a May 2020 market update, Blackmores revealed it has seen a significant increase in demand for its immunity products. However, this demand has been offset by weaker demand across other segments of the business. Furthermore, immunity products only constitute a small part of the company’s overall product portfolio.

Blackmores also reported that supply chain constraints have restricted the company’s ability to keep up with demand in some of its product segments. In particular, Blackmores has been experiencing difficulties accessing some of its internationally-sourced materials.

Ramp up of Asian growth strategy

Blackmores also recently provided an update on the company’s plan to further accelerate its Asian expansion strategy, particularly in China.

Blackmores will continue to expand both its organisational capabilities and partnership opportunities within this highly lucrative market. This will include driving innovation with a new ‘Modern Parenting’ product line.

The company will also inject more funds into its rapidly growing South East Asian business, including identifying new health and nutritional demand areas. Furthermore, Blackmores will increase investment in its IT capabilities, as well as its in-store product advisors across Indonesian operations.

India is another market in which Blackmores is ramping up investment. The company is allocating further working capital to initially target three large Indian cities. This will then act as a launching pad for further growth in this potentially huge market for the Aussie supplements manufacturer.

Lastly, Blackmores is looking to improve its digital capabilities throughout the entire Asian region.

Is the Blackmores share price a buy right now?

The Blackmore’s share price is in my buy zone right now. But only just…

I’m encouraged by the progress Blackmores is making with its Asian strategy. I believe India, in particular, offers Blackmores exciting potential for growth.

Having said that, I would want to see further evidence of its success in turning the business around before classifying Blackmores as a definite buy right now.

More reading

• Here’s where this ASX fund manager sees value for investors
• Here are all the ASX 200 companies that announced capital raisings in May
• ASX 200 rises again, ASX banks push higher
• Top brokers name 3 ASX 200 shares to sell today
• Why ANZ, Blackmores, IDP Education, & Nearmap shares are racing higher

Motley Fool contributor Phil Harpur owns shares of Blackmores Limited. The Motley Fool Australia owns shares of and has recommended Blackmores Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Is the Blackmores share price in the buy zone? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2ANtzS4